Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19

@article{Brunetti2020ColchicineTW,
  title={Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19},
  author={Luigi Brunetti and Oumou Diawara and Andrew Tsai and Bonnie L. Firestein and Ronald G. Nahass and George Poiani and Naomi Schlesinger},
  journal={Journal of Clinical Medicine},
  year={2020},
  volume={9}
}
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints… 

Figures and Tables from this paper

Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
TLDR
In hospitalized COVID-19 patients, colchicine treatment neither improved the clinical status, nor the inflammatory response, over the standard treatment, Nevertheless, a preventive effect for further clinical deterioration might be possible.
Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With Coronavirus Disease-19
TLDR
Patients hospitalized with COVID-19 and evidence of cardiac injury did not benefit from colchicine therapy and key secondary endpoints included the individual components of the primary endpoint and change in and at least 2-grade reduction in the World Health Organization Ordinal Scale at 30 days.
Repurposing Colchicine in Treating Patients with COVID-19: A Systematic Review and Meta-Analysis
TLDR
It is found that colchicine treatment was associated with a significantly lower risk of mortality in patients with COVID-19, however, this benefit was not observed in the subgroup analysis of randomized controlled trials.
Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
TLDR
Colchicine is safe but not effective in the treatment of severe COVID-19, and patients had higher BUN and lower serum levels of IL-8, IL-12p70, and IL-17A after treatment.
Colchicine use in patients with COVID-19: A systematic review and meta-analysis
TLDR
Colchicine may reduce the risk of mortality in individuals with COVID-19 and further prospective investigation is warranted to determine the efficacy of colchicines as treatment in CO VID-19 patients in various care settings of the disease.
Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis
TLDR
Observations could support the maintenance of colchicine prescription in those patients already being treated, as it is not associated with a worse prognosis, and Generalized Boosted Models and Empirical Balancing Calibration Weighting methods showed the best balance for COVID-19-related hospital admissions.
Impact of colchicine on mortality and morbidity in COVID-19: a systematic review
TLDR
Until further research can establish the efficacy of colchicine in COVID-19, the use of col chicine shall be restricted to clinical trials.
COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study
TLDR
Rates of comorbid diseases and IL-1 inhibitor use for FMF were observed to be increased in FMF patients hospitalized for COVID-19, and an increasing trend in the frequency ofComorbid Diseases and IL—1 inhibitor usage was observed in hospitalized patients.
Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials
TLDR
Clinical trials need to be carried out that allow effective evaluation of colchicine in COVID-19 patients, with dimer levels, all-cause mortality and mechanical ventilation remaining seemingly unaffected.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
Colchicine treatment in community healthcare setting to prevent severe COVID-19.
TLDR
Hospitalised patients with severe COVID-19 are currently being treated with anti-cytokine biological drugs including the IL-1 receptor antagonist anakinra, the anti-granulocyte-macrophage colony-stimulating factor mavrilimumab and theIL-6 receptor blockers tocilizumab and sarilumab, but these targeted approaches do not seem to induce a prompt recovery as optimistically expected.
Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease
TLDR
It is suggested that COVID-19 represents the first example of an infectious disease that can be successfully treated with anti-rheumatic drugs and a rationale for the use of IL-1 blockade with anakinra (IL-1 receptor antagonist) was postulated and trials are underway.
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
TLDR
In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.
Colchicine in COVID-19: an Old Drug, New Use
TLDR
It is discussed how colchicine interferes with several inflammatory pathways, including inhibition of neutrophil chemotaxis, adhesion, and mobilization; disruption of superoxide production, inflammasome inhibition, and tumor necrosis factor reduction; and its possible antiviral properties.
Colchicine as a possible therapeutic option in COVID-19 infection
TLDR
It is argued that low pH levels secondary to colchicine may increase the viral load of SARS-CoV-2 and, therefore, cytokine storms will be more severe and col chicine can be a good therapeutic option because of several effects in the immunology system involved in Sars-CoVs infection and in the acute respiratory distress syndrome (ARDS).
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019
TLDR
A role for colchicine in the treatment of patients with coronavirus disease 2019 is suggested, with results suggesting a smaller increase in dimerized plasma fragment D compared with patients in the control group.
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome
TLDR
A proof-of-concept study that may support the rationale of use of colchicine for the treatment of COVID-19, and its effects compared with ‘standard- of-care’ (SoC).
Colchicine may not be effective in COVID-19 infection; it may even be harmful?
TLDR
Recently, it has been suggested that colchicine may be effective in COVID-19 infection and reduce cytokine storm seen during the COIDs, which suggests that the virus causes more severe infection at low cytosolic pH.
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
TLDR
Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.
...
...